Eli Lilly and Co. stock target raised to USD 1,316, pre-market slightly higher
Published on 10/22/2026 at 08:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeerink raises Lilly target
- The analyst firm lifted its Eli Lilly target to USD 1,316 from USD 1,309 on October 21, 2026.
- Lilly's third-quarter 2026 earnings call is scheduled for October 29, 2026.
- Eli Lilly and Co. stock trades pre-market at EUR 1,139.00 at 8:01 a.m. CEST at Lang & Schwarz on October 22, 2026, plus 0.94 percent above the Xetra close of October 21, 2026.
On October 21, 2026, Leerink raised its price target for Eli Lilly and Company to USD 1,316 from USD 1,309 while maintaining an Outperform rating, as reported by Markets Insider. Eli Lilly and Co. stock trades pre-market at EUR 1,139.00 at 8:01 a.m. CEST at Lang & Schwarz on October 22, 2026, plus 0.94 percent above the Xetra close of October 21, 2026 (EUR 1,128.40).
Leerink revises its view
The analyst firm cited continued upward pressure on consensus expectations and strong obesity-drug adoption, particularly in markets outside the United States. The rating remained Outperform, according to the report published October 21, 2026.
Ahead of the Xetra open
The difference is plus EUR 10.60 in absolute terms, placing the pre-market quote above the reference closing level. The bid and ask indicate a spread below 1.00 percent of the price. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Eli Lilly and Co. stock.
The group and its market
Eli Lilly researches, develops and commercializes human medicines, earning revenue from pharmaceutical products across therapeutic areas including diabetes, oncology, autoimmune and neurological conditions. The company's Q3 2026 earnings call is scheduled for October 29, 2026, at 10:00 a.m. EDT, according to Eli Lilly and Company. Market context: Market report S&P 500.
